Enzastaurin HCl
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Colonic Neoplasms
Conditions
Colonic Neoplasms
Trial Timeline
Aug 1, 2005 → Mar 1, 2008
NCT ID
NCT00192114About Enzastaurin HCl
Enzastaurin HCl is a phase 2 stage product being developed by Eli Lilly for Colonic Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT00192114. Target conditions include Colonic Neoplasms.
What happened to similar drugs?
2 of 3 similar drugs in Colonic Neoplasms were approved
Approved (2) Terminated (1) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00192114 | Phase 2 | Completed |
| NCT00105092 | Phase 2 | Completed |
Competing Products
6 competing products in Colonic Neoplasms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Entereg + Entereg + placebo | Merck | Phase 2 | 35 |
| Indium labeled IMP-205xm734 | Gilead Sciences | Phase 1 | 29 |
| psyllium fibre (dietary supplement) + wheat bran (dietary supplement) + rice wheat (placebo) | Pfizer | Pre-clinical | 26 |
| Methylnaltrexone Bromide (MNTX) + Placebo | Pfizer | Approved | 35 |
| oxaliplatin | Sanofi | Approved | 43 |
| Oxaliplatin (SR96669) | Sanofi | Phase 3 | 40 |